Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
(NASDAQ: HELP) Delayed: 14.02 +0.55 (4.08%)
Previous Close $13.47    52 Week High $ 
Open $13.68    52 Week Low $ 
Day High $14.17    P/E N/A 
Day Low $13.12    EPS $ 
Volume 3,334,234       

(NASDAQ: HELP) Delayed: 14.02 +0.55 (4.08%)
Previous Close $13.47    52 Week High $ 
Open $13.68    52 Week Low $ 
Day High $14.17    P/E N/A 
Day Low $13.12    EPS $ 
Volume 3,334,234